Will Maintenance Therapy Provide a Real Benefit?

Web Exclusives
Download Newsletter

In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones. As treatment of the disease continues to evolve, so do costs, prompting healthcare stakeholders to increasingly seek value-based approaches to patient management. The goal of this newsletter series, published by the Association for Value-Based Cancer Care™, is to report on the latest clinical advances in myeloma and provide stakeholder perspectives on how emerging data can be used to promote high-quality, cost-effective care. Previous newsletters in this series (available at explored the importance of cytogenetic findings as they relate to therapeutic decision-making, the selection of effective induction regimens for transplant-eligible and -ineligible patients, the use of imaging techniques for evaluating myeloma-related bone disease, and the interpretation of survival data from clinical trials. In this sixth newsletter, we will discuss the evolving role of maintenance therapy in MM.

Last modified: March 7, 2019
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology